ST receptor binding compounds and methods of using the same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
A61K-035/12
출원번호
UP-0724983
(2000-11-28)
등록번호
US-7744870
(2010-07-19)
발명자
/ 주소
Waldman, Scott A.
출원인 / 주소
Thomas Jefferson University
대리인 / 주소
Pepper Hamilton LLP
인용정보
피인용 횟수 :
1인용 특허 :
61
초록▼
Conjugated compounds which comprises an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent, and a conjugated compound which comprises an ST receptor binding moiety and a radiostable active
Conjugated compounds which comprises an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent, and a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive, active moiety are disclosed. Methods of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent, and a therapeutically effective amount of a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radiostable active moiety are disclosed. Methods of radioimaging metastasized colorectal cancer cells comprising the steps of first administering to an individual suspected of having metastasized colorectal cancer cells, a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent, and conjugated compound that comprises an ST receptor binding moiety and a radioactive active moiety wherein the conjugated compound is present in an amount effective for diagnostic use in humans suffering from colorectal cancer and then detecting the localization and accumulation of radioactivity in the individual's body are disclosed.
대표청구항▼
The invention claimed is: 1. A method of treating an individual suspected of suffering from metastatic colorectal cancer comprising the step of administering to said individual a pharmaceutical composition that comprises: a) a heat stable enterotoxin (ST) receptor ligand in combination with; b) an
The invention claimed is: 1. A method of treating an individual suspected of suffering from metastatic colorectal cancer comprising the step of administering to said individual a pharmaceutical composition that comprises: a) a heat stable enterotoxin (ST) receptor ligand in combination with; b) an active agent in an amount effective to cause a cytotoxic or cytostatic effect on metastasized colorectal cancer cells without causing lethal side effects on the individual, wherein the active agent causes cell death, inhibits cell division or induces differentiation; and c) a pharmaceutically acceptable carrier or diluent wherein said ST receptor ligand is an antibody, Fab or F(AB)2. 2. The method of claim 1 wherein said ST receptor ligand is an antibody. 3. The method of claim 1 wherein said active agent causes cell death. 4. The method of claim 1 wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole. 5. The method of claim 1 wherein said pharmaceutical composition combination is administered intravenously. 6. The method of claim 4 wherein said ST receptor ligand is an antibody. 7. The method of claim 5 wherein said ST receptor ligand is an antibody. 8. The method of claim 1 wherein said ST receptor ligand is a Fab. 9. The method of claim 4 wherein said ST receptor ligand is a Fab. 10. The method of claim 5 wherein said ST receptor ligand is a Fab. 11. The method of claim 1 wherein said ST receptor ligand is a F(ab)2. 12. The method of claim 4 wherein said ST receptor ligand is a F(ab)2. 13. The method of claim 5 wherein said ST receptor ligand is a F(ab)2. 14. The method of claim 3 wherein said ST receptor ligand is an antibody. 15. The method of claim 3 wherein said ST receptor ligand is a F(ab). 16. The method of claim 3 wherein said ST receptor ligand is a F(ab)2. 17. The method of claim 1 wherein said active agent is a chemotherapeutic agent. 18. The method of claim 1 wherein said active agent is a cytotoxic chemotherapeutic agent. 19. A method of treating an individual suffering from metastatic colorectal cancer comprising the step of administering to said individual an amount of a pharmaceutical composition effective to therapeutically eliminate metastasized colorectal cancer cells, wherein said pharmaceutical compositions comprises: a) a heat stable enterotoxin (ST) receptor ligand; b) an active agent, wherein the active agent causes cell death, inhibits cell division or induces differentiation: and a pharmaceutically acceptable carrier or diluent, wherein said ST receptor ligand is an antibody, Fab or F(AB)2. 20. The method of claim 19 wherein said ST receptor ligand is an antibody. 21. The method of claim 19 wherein said active agent causes cell death. 22. The method of claim 19 wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole. 23. The method of claim 19 wherein said pharmaceutical composition is administered intravenously. 24. The method of claim 22 wherein said ST receptor ligand is an antibody. 25. The method of claim 23 wherein said ST receptor ligand is an antibody. 26. The method of claim 19 wherein said ST receptor ligand is a Fab. 27. The method of claim 22 wherein said ST receptor ligand is a Fab. 28. The method of claim 23 wherein said ST receptor ligand is a Fab. 29. The method of claim 19 wherein said ST receptor ligand is a F(ab)2. 30. The method of claim 23 wherein said ST receptor ligand is a F(ab)2. 31. The method of claim 23 wherein said ST receptor ligand is a F(ab)2. 32. The method of claim 21 wherein said ST receptor ligand is an antibody. 33. The method of claim 21 wherein said ST receptor ligand is a Fab. 34. The method of claim 21 wherein said ST receptor ligand is a F(ab)2. 35. The method of claim 19 wherein said active agent is a chemotherapeutic agent. 36. The method of claim 19 wherein said active agent is a cytotoxic chemotherapeutic agent. 37. A method of treating an individual suffering from metastatic colorectal cancer comprising the step of administering to said individual a conjugated compound in an amount effective to cause a cytotoxic or cytostatic effect on metastasized colorectal cancer cells without causing lethal side effects on the individual, wherein said conjugated compound comprises a) a heat stable enterotoxin (ST) receptor binding moiety which is an antibody or a fragment thereof; b) an active moiety which is an active agent that causes cell death, inhibits cell division or induces differentiation. 38. The method of claim 37 wherein said ST receptor binding moiety is an antibody. 39. The method of claim 37 wherein said ST receptor binding moiety is a FAb. 40. The method of claim 37 wherein said ST receptor binding moiety is an F(Ab)2. 41. The method of claim 37 wherein said active moiety is an active agent that causes cell death. 42. The method of claim 37 wherein said active moiety is a chemotherapeutic agent. 43. The method of claim 37 wherein said active moiety is a cytotoxic chemotherapeutic agent. 44. The method of claim 37 wherein said active moiety is selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole. 45. The method of claim 37 wherein said conjugated compound is administered intravenously. 46. A method of treating an individual suspected of suffering from metastatic colorectal cancer or suffering from metastatic colorectal cancer comprising administering to said individual a heat stable enterotoxin (ST) receptor ligand in combination with an active agent in an amount effective to cause a cytotoxic or cytostatic effect on metastasized colorectal cancer cells without causing lethal side effects on the individual, wherein the active agent causes cell death, inhibits cell division or induces differentiation; and wherein said ST receptor ligand is an antibody, Fab or F(AB)2.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (61)
Albertsen Hans (Salt Lake City UT) Anand Rakesh (Cheshire UT GB2) Carlson Mary (Salt Lake City UT) Groden Joanna (Salt Lake City UT) Hedge Philip J. (Cheshire UT GB2) Joslyn Geoff (Salt Lake City UT), APC gene and nucleic acid probes derived therefrom.
Goers John W. F. (Atascadero CA) King Hurley D. (Yardley PA) Lee Chyi (New Brunswick NJ) Coughlin Daniel J. (Plainsboro NJ) Alvarez Vernon L. (Morrisville PA) Rodwell John D. (Yardley PA) McKearn Tho, Antibody-therapeutic agent conjugates.
Hoke Glenn D. (Mt. Airy MD) Bradley Matthews O. (Laytonsville MD) Williams Taffy J. (Lansdale PA) Lee Che-Hung (Silver Spring MD), Antisense oligonucleotides directed against human ELAM-I RNA.
Cody Donna R. (Saline MI) DeWitt Sheila H. H. (Dexter MI) Hodges John C. (Ann Arbor MI) Kiely John S. (Ann Arbor MI) Moos Walter H. (Oakland CA) Pavia Michael R. (Newton MA) Roth Bruce D. (Ann Arbor , Apparatus for multiple simultaneous synthesis.
Klipstein Frederick A. (Rochester NY) Engert Richard E. (Webster NY) Clements John D. (Pittsford NY), Composition of a novel immunogen for protection against diarrheal disease caused by enterotoxigenic Escherichia coli<.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Carman William F. (Glasgow GB6) Decker Richard H. (Deerfield IL) Wallace Lesley (Glasgow GB6) Mimms Larry T. (Lake Villa IL) Solomon Larry R. (Mundelein IL), Hepatitis B virus mutants, reagents and methods for detection.
Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA) Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA), Large scale photolithographic solid phase synthesis of an array of polymers.
Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA) Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA), Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof.
Vogelstein Bert (Baltimore MD) Kinzler Kenneth W. (Baltimore MD) White Raymond (Salt Lake City UT) Nakamura Yusuke (Tokyo JPX), MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans.
Ceriani Roberto L. (1089 Via Roble Lafayette CA 94549) Peterson Jerry A. (5916 Chabot Rd. Oakland CA 94618), Method and compositions for carcinoma diagnosis.
Welt Sydney (New York NY) Divgi Chaitanya R. (New York NY) Yeh Samual (New York NY) Old Lloyd J. (New York NY) Oettgen Herbert F. (New Canaan CT) Real Francisco X. (Barcelona ESX) Sakamoto Junichi (C, Method of imaging colorectal carcinoma lesion and composition for use therein.
Trentham David E. (North Quincy MA) Weiner Howard L. (Brookline MA) Hafler David A. (West Newton MA), Method of treating rheumatoid arthritis with type II collagen.
Innis Michael A. (Moraga CA) Myambo Kenneth B. (Pittsburg CA) Gelfand David H. (Oakland CA) Brow Mary Ann D. (Oakland CA), Methods for DNA sequencing with thermus aquaticus DNA polymerase.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Gelfand David H. (Oakland CA) Horn Glenn (Emeryville CA) Saiki Randall K. (Richmond CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Coolidge Thomas R. (Falls Village CT) Lewis William (Lincoln NE) Schuster Sheldon M. (Gainesville FL) Wylie Dwane (Lincoln NE) Wagner Fred W. (Walton NE) Stout Jay (Lincoln NE) van Heeke Gino (Gaines, Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques.
Barrett Ronald W. (Sunnyvale CA) Pirrung Michael C. (Durham NC) Stryer Lubert (Stanford CA) Holmes Christopher P. (Sunnyvale CA) Sundberg Steven A. (San Francisco CA), Spatially-addressable immobilization of anti-ligands on surfaces.
McGall Glenn H. (Mountain View CA) Fodor Stephen P. A. (Palo Alto CA) Sheldon Edward L. (Menlo Park CA), Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces.
Duflot Anabela (Vanves FRX) Gras Hlne (Hem FRX) Tartar Andr (Vitry-en-Artois FRX) Duflot Edith (Cachan FRX) Boquet Patrice (Creteil FRX), Synthetic ST toxin, process for its preparation and its use as a vaccinating agent.
Gluck Reinhard,CHX ; Klein Peter,CHX ; Herrmann Peter,CHX ; Walti Ernst Rudolf,CHX, Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems.
Ridker Paul ; Hennekens Charles H., Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atheroscl.
Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA) Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA), Very large scale immobilized polymer synthesis.
Winkler James L. (Palo Alto CA) Fodor Stephen P. A. (Palo Alto CA) Buchko Christopher J. (Palo Alto CA) Ross Debra A. (Fremont CA) Aldwin Lois (San Mateo CA), Very large scale immobilized polymer synthesis using mechanically directed flow paths.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.